Liquidia Corp(LQDA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:40 PM ET (Korea 9/12 08:40)
Full metrics table
| Index | RUT | P/E | 48.92 | EPS (ttm) | 1.36 | Insider Own | 13.47% | Shs Outstand | 89.1M | Perf Week | -2.75% |
| Market Cap | 5.97B | Forward P/E | 11.99 | EPS next Y | 81.47% | Insider Trans | -22.23% | Shs Float | 77.5M | Perf Month | -15.29% |
| Enterprise Value | 5.87B | PEG | - | EPS next Q | 0.88 | Inst Own | 79.99% | Short Float | 15.31% | Perf Quarter | -6.82% |
| Income | 0.14B | P/S | 13.25 | EPS this Y | 483.5% | Inst Trans | 15.71% | Short Ratio | 6.75 | Perf Half Y | 77.59% |
| Sales | 0.45B | P/B | 30.48 | EPS next 5Y | - | ROA | 35.57% | Short Interest | 11.86M | Perf YTD | 93.51% |
| Book/sh | 2.19 | P/C | 21.02 | EPS past 3/5Y | -5.98% 14.6% | ROE | 131.82% | 52W High | -28.7% ($93.61) | Perf Year | 147.19% |
| Cash/sh | 3.17 | P/FCF | 39.64 | Sales past 3/5Y | 114.98% 192.49% | ROIC | 42.89% | 52W Low | 215.63% ($21.15) | Perf 3Y | 845.33% |
| Dividend Est. | - | EV/EBITDA | 34.49 | EPS Y/Y TTM | 193.03% | Gross Margin | 92.3% | Volatility(W/M) | 3.14% 5.11% | Perf 5Y | 2353.68% |
| Dividend TTM | - | EV/Sales | 13.02 | Sales Y/Y TTM | 2233.65% | Oper. Margin | 37.39% | ATR (14) | 3.5 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.12 | EPS Q/Q | 251.69% | Profit Margin | 30.74% | RSI (14) | 38.02 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.31 | Sales Q/Q | 1842.73% | SMA20 | -4.97% ($70.23) | Beta | 0.54 | Target Price | $107.75 |
| Payout | - | Debt/Eq | 0.94 | Earnings | 2026/8/12 | SMA50 | -14.08% ($77.68) | Rel Volume | 0.44 | Prev Close | $67.85 |
| Employees | 216 | LT Debt/Eq | 0.66 | EPS/Sales Surpr. | -2.34% 1.9% | SMA200 | 28.04% ($52.12) | Avg Volume(3M) | 1.76M | Price | $66.74 |
| IPO | 2018/7/26 | Option/Short | Yes/Yes | Trades | 12872 | Volume | 777,801 | Change | -1.64% |
Company
LQDA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A commercial-stage pharmaceutical company that develops and sells treatments for lung diseases, including pulmonary arterial hypertension. The company recently launched an inhaled therapy for pulmonary arterial hypertension and is rapidly growing sales, making it a healthcare stock with proprietary inhaled formulation technology. Its value hinges on sales of its key therapy, expanding prescriptions, and the competitive landscape.
Over the past 1 year, roughly in the middle
29% below its 1-year high.
LQDA makes money exceptionally well
37.39% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +483.5% this year.
Tap to view numbers
The price looks about right
Trading at 48.9 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +845.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 80.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PJP 0.03%
QMOM 0.02%
XPH 0.02%
PTH 0.01%
PILL 0.01%It ranks #4 in the industry
Based on market cap of $6B.
LQDA $6B PER 48.9
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is LQDA?
LQDA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of LQDA?
The market cap of LQDA is approximately $6.0B, ranking 1,254 within its sector.
What is the P/E ratio of LQDA?
LQDA has a P/E ratio of approximately 48.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for LQDA?
LQDA has recorded a 52-week high of $93.61 and a low of $21.15.
